Cargando…

Diastolic heart failure is a new clinical entity of trastuzumab-induced cardiotoxicity: a case report

BACKGROUND: Cancer therapy-related cardiac dysfunction (CTRCD) is defined as a decrease in the left ventricular ejection fraction (LVEF) of >10% to a value below the lower limit of normal or relative reduction in global longitudinal strain (GLS) >15% from baseline after cancer treatment. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujita, Kana, Matsumoto, Kensuke, Kishi, Atsuhiko, Kawasaki, Satoru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792275/ https://www.ncbi.nlm.nih.gov/pubmed/36582596 http://dx.doi.org/10.1093/ehjcr/ytac470

Ejemplares similares

Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
por: Reuvekamp, E. J., et al.
Publicado: (2015)

Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014)

Doxorubicin‐induced and trastuzumab‐induced cardiotoxicity in mice is not prevented by metoprolol
por: Nicol, Martin, et al.
Publicado: (2021)

Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer
por: Sato, Akihiko, et al.
Publicado: (2019)

The pathophysiology of diastolic heart failure
por: Phan, Thanh Trung, et al.
Publicado: (2010)

Diastolic Function in Heart Failure
por: Kovács, Sándor J
Publicado: (2015)

Detection of Subclinical Trastuzumab-Induced Cardiotoxicity in Patients with Breast Cancer
por: dos Santos, Marília Harumi Higuchi
Publicado: (2013)

Ginsenoside Rg2 Attenuated Trastuzumab-Induced Cardiotoxicity in Rats
por: Liu, Guang, et al.
Publicado: (2022)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
por: Eaton, Holden, et al.
Publicado: (2023)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Lithium-induced Cardiotoxicity: A Rare Clinical Entity
por: Acharya, Sudeep, et al.
Publicado: (2020)

A Case of Trastuzumab-Associated Cardiomyopathy Presenting as an Acute Coronary Syndrome: Acute Trastuzumab Cardiotoxicity
por: Hidalgo, Sylvana, et al.
Publicado: (2013)

Echocardiographic evaluation of diastolic heart failure
por: Lo, Queenie, et al.
Publicado: (2015)

Whole exome sequencing to identify genetic markers for trastuzumab‐induced cardiotoxicity
por: Udagawa, Chihiro, et al.
Publicado: (2018)

Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects
por: Galderisi, Maurizio
Publicado: (2005)

Wandering fourth heart sound
por: Kunigita, Takahiro, et al.
Publicado: (2022)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Trastuzumab-related cardiotoxicity: what do we know in 2020?
por: Liu, Jia, et al.
Publicado: (2020)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
por: Chang, Wei‐Ting, et al.
Publicado: (2021)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
por: Méndez-Valdés, Gabriel, et al.
Publicado: (2023)

Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
por: Zhou, Shijie, et al.
Publicado: (2023)

Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
por: Tanaka, Satoru, et al.
Publicado: (2017)

The clinical quandary of left and right ventricular diastolic dysfunction and diastolic heart failure
por: Schwarz, Ernst R, et al.
Publicado: (2010)

Correction: Lithium-induced Cardiotoxicity: A Rare Clinical Entity
por: Acharya, Sudeep, et al.
Publicado: (2020)

The role of renin angiotensin system antagonists in the prevention of doxorubicin and trastuzumab induced cardiotoxicity
por: Akolkar, Gauri, et al.
Publicado: (2015)

Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis
por: Jawa, Zeeshan, et al.
Publicado: (2016)

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
por: Altomare, Claudia, et al.
Publicado: (2021)

Involvement of kallikrein‐PAR2‐proinflammatory pathway in severe trastuzumab‐induced cardiotoxicity
por: Sasaki, Ritsuko, et al.
Publicado: (2022)

Diastolic Heart Failure: A Concise Review
por: Aziz, Fahad, et al.
Publicado: (2013)

Modeling Pathologies of Diastolic and Systolic Heart Failure
por: Genet, M., et al.
Publicado: (2015)

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
por: Soga, Fumitaka, et al.
Publicado: (2018)

Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors
por: Soga, Fumitaka, et al.
Publicado: (2021)

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
por: Cuomo, Alessandra, et al.
Publicado: (2019)

Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity
por: Jiang, Jiangsong, et al.
Publicado: (2017)

Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy
por: Gabani, Mohanad, et al.
Publicado: (2021)

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021)

Coq10 for preventing cardiotoxicity in breast cancer patients treated with trastuzumab
por: Al-Hammadi, Nawal, et al.
Publicado: (2023)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
por: Shrivastva, Sarita, et al.
Publicado: (2023)

Characteristics of Myocardial Deformation and Rotation in Subjects With Diastolic Dysfunction Without Diastolic Heart Failure
por: Jang, Hee Sang, et al.
Publicado: (2009)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
por: Ito, Mayuko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i1lu3u23rgg9rojkv1gjv38c68